UK Edition. Click here for US version.
COSITAM XL 400 MICROGRAM PROLONGED-RELEASE TABLETS
Active substance(s): TAMSULOSIN HYDROCHLORIDE
NAME OF THE MEDICINAL PRODUCT
Cositam XL 400 microgram prolonged-release tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged-release tablet contains 400 microgram tamsulosin hydrochloride, equivalent to 367 microgram tamsulosin. For a full list of excipients, see section 6.1.
Prolonged-release tablet. White, unscored, round tablets with a diameter of 9 mm, debossed on one side with "T9SL and 0.4 on the other side.
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Posology and method of administration
Oral use. One tablet daily. Tamsulosin can be taken independently of food. The tablet must be swallowed whole and not be crunched or chewed as this interferes with the prolonged release of the active substance.
No dose adjustment is warranted in renal impairment. No dose adjustment is warranted in patients with mild to moderate hepatic insufficiency (see also 4.3, Contraindications). Paediatric population The safety and efficacy of tamsulosin in children and adolescents have not been established. Currently available data are described in section 5.1. There is no relevant indication for use of tamsulosin in children.
Hypersensitivity to tamsulosin hydrochloride, including drug-induced angioedema or to any of the excipients. A history of orthostatic hypotension. Severe hepatic insufficiency.
Special warnings and precautions for use
As with other 1-adrenoceptor antagonists, a reduction in blood pressure can occur in individual cases during treatment with tamsulosin, as a result of which, rarely, syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness), the patient should sit or lie down until the symptoms have disappeared. Before therapy with tamsulosin is initiated, the patient should be examined in order to exclude the presence of other conditions, which can cause the same symptoms as benign prostatic hyperplasia. Digital rectal examination and, when necessary, determination of prostate specific antigen (PSA) should be performed before treatment and at regular intervals afterwards. The treatment of patients with severe renal impairment (creatinine clearance of < 10 ml/min) should be approached with caution, as these patients have not been studied. The Intraoperative Floppy Iris Syndrome (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. IFIS may lead to increased procedural complications during the operation. The initiation of therapy with tamsulosin in patients for whom cataract surgery is scheduled is not recommended.
Discontinuing tamsulosin 1-2 weeks prior to cataract surgery is anecdotally considered helpful, but the benefit and duration of stopping the therapy prior to cataract surgery has not yet been established. During pre-operative assessment, cataract surgeons and ophthalmic teams should consider whether patients scheduled for cataract surgery are being or have been treated with tamsulosin in order to ensure that appropriate measures will be in place to manage the IFIS during surgery. It is possible that a remnant of the tablet is observed in the faeces.
Interaction with other medicinal products and other forms of interaction
Interaction studies have only been performed in adults. No interactions have been seen when tamsulosin was given concomitantly with either atenolol, enalapril or theophylline. Concomitant cimetidine brings about a rise in plasma levels of tamsulosin, whereas furosemide a fall, but as levels remain within the normal range posology need not be adjusted. In vitro, neither diazepam nor propranolol, trichlormethiazide, chlormadinone, amitriptyline, diclofenac, glibenclamide, simvastatin and warfarin change the free fraction of tamsulosin in human plasma. Neither does tamsulosin change the free fractions of diazepam, propranolol, trichlormethiazide and chlormadinone. No interactions at the level of hepatic metabolism have been seen during in vitro studies with liver microsomal fractions (representative of the cytochrome P450-linked drug metabolising enzyme system), involving amitriptyline, salbutamol, glibenclamide and finasteride. Diclofenac and warfarin, however, may increase the elimination rate of tamsulosin. Concurrent administration of other hypotensive effects.
antagonists could lead to
Pregnancy and lactation
Not applicable, as tamsulosin is intended for male patients only.
Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. However, patients should be aware of the fact that dizziness can occur.
Nervous systems disorders Cardiac disorders Vascular disorders Respiratory, thoracic and mediastinal disorders
Headache Palpitations Orthostatic hypotension Rhinitis
Skin and subcutaneous tissue disorders Reproductive system and breast disorders General disorders and administration site conditions Ejaculation disorders
Constipation, diarrhoea, nausea, vomiting Rash, pruritus, urticaria
During cataract surgery a small pupil situation, known as Intraoperative Floppy Iris Syndrome (IFIS) has been associated with therapy of tamsulosin during postmarketing surveillance (see section 4.4). Post-marketing experience: In addition to the adverse events listed above, atrial fibrillation, arrhythmia, tachycardia and dyspnoea have been reported in association with tamsulosin use. Because these spontaneously reported events are from the worldwide post marketing experience, the frequency of events and the role of tamsulosin in their causation cannot be reliably determined.
MedDRA system organ class
Common ( 1/100 to <1/10)
Uncommon ( 1/1,000 to <1/100)
Rare ( 1/10,000 to <1/1,000)
Very rare (<1/10,000)
StevensJohnson syndrome Priapism
Acute overdose with 5 mg of tamsulosin hydrochloride has been reported. Acute hypotension (systolic blood pressure 70 mm Hg), vomiting and diarrhoea were observed, which were treated with fluid replacement and the patient could be discharged the same day. In case of acute hypotension occurring after overdosage cardiovascular support should be given. Blood pressure can be restored and heart rate brought back to normal by lying the patient down. If this does not help then volume expanders and, when necessary, vasopressors could be employed. Renal function should be monitored and general supportive measures applied. Dialysis is unlikely to be of help as tamsulosin is very highly bound to plasma proteins. Measures, such as emesis, can be taken to impede absorption. When large quantities are involved, gastric lavage can be applied and activated charcoal and an osmotic laxative, such as sodium sulphate, can be administered.
Pharmacotherapeutic group: Drugs used in benign prostatic hypertrophy, Alphaadrenoreceptor antagonists; ATC code: G04C A02. Mechanism of action Tamsulosin binds selectively and competitively to the postsynaptic 1-adrenoceptors, in particular to subtypes 1A and 1D. It brings about relaxation of prostatic and urethral smooth muscle. Pharmacodynamic effects Tamsulosin increases the maximum urinary flow rate. It relieves obstruction by relaxing smooth muscle in prostate and urethra thereby improving voiding symptoms. It also improves the storage symptoms in which bladder instability plays an important role. These effects on storage and voiding symptoms are maintained during long-term therapy. Observational data indicate that use of tamsulosin may lead to a delay in the need for surgery or catheterization. antagonists can reduce blood pressure by lowering peripheral resistance. No reduction in blood pressure of any clinical significance was observed during studies with tamsulosin.
Paediatric population A double-blind, randomized, placebo-controlled, dose ranging study was performed in children with neuropathic bladder. A total of 161 children were randomized and treated at 1 of 3 dose levels of tamsulosin (low [0.001 to 0.002 mg/kg], medium [0.002 to 0.004 mg/kg], and high [0.004 to 0.008 mg/kg]), or placebo. A response was defined as a primary endpoint with patients who decrease their detrusor leak point pressure (LPP) to <40 cm H2O based upon two evaluations on the same day. Secondary endpoint were: Actual and percent change from baseline in detrusor leak point pressure, improvement or stabilization of hydronephrosis and hydroureter and change in urine volumes obtained by catheterisation and number of times wet at time of catheterisation as recorded in catheterisation diaries. No statistically significant differences were found between the placebo group and any of the 3 tamsulosin dose groups for either the primary or any secondary endpoint. Additional exploratory analyses in subgroups confirmed these findings (e.g. age, anti-cholinergic use, weight, geographic regions). No dose response was observed for any dose level.
Absorption The Tamsulosin prolonged-release formulation provides consistent slow release of tamsulosin, resulting in an adequate exposure, with little fluctuation, over 24 hours. Tamsulosin administered as Tamsulosin prolonged-release tablets is absorbed from the intestine. Of the administered dose, approximately 57% is estimated to be absorbed. The rate and extent of absorption of tamsulosin administered as Tamsulosin hydrochloride prolonged release tablets are not affected by food. Tamsulosin shows linear pharmacokinetics. After a single dose of tamsulosin in the fasted state, plasma concentrations of tamsulosin peak at a median time of 6 hours. In steady state, which is reached by day 4 of multiple dosing, plasma concentrations of tamsulosin peak at 4 to 6 hours, in the fasted and fed state. Peak plasma concentrations increase from approximately 6 ng/ml after the first dose to 11 ng/ml in steady state. As a result of the prolonged-release characteristics of Tamsulosin prolonged-release tablets the trough concentration of tamsulosin in plasma amounts to 40% of the peak plasma concentration under fasted and fed conditions. There is a considerable inter-patient variation in plasma levels both after single and multiple dosing. Distribution
In man, tamsulosin is about 99% bound to plasma proteins. The volume of distribution is small (about 0.2 l/kg). Biotransformation Tamsulosin has a low first pass effect, being metabolised slowly. Most tamsulosin is present in plasma in the form of unchanged active substance. It is metabolised in the liver. In rats, hardly any induction of microsomal liver enzymes was seen to be caused by tamsulosin. None of the metabolites are more active than the original compound. Elimination Tamsulosin and its metabolites are mainly excreted in the urine. The amount excreted as unchanged active substance is estimated to be about 4 - 6% of the dose, administered as Tamsulosin prolonged-release tablets. After a single dose of tamsulosin and in steady state, elimination half-lives of about 19 and 15 hours, respectively, have been measured.
Preclinical safety data
Single and repeat dose toxicity studies were performed in mice, rats and dogs. In addition, reproduction toxicity in rats, carcinogenicity in mice and rats and in vivo and in vitro genotoxicity were examined. The general toxicity profile, as seen with high doses of tamsulosin, is consistent with the known pharmacological actions of the -adrenoceptor antagonists. At very high dose levels the ECG was altered in dogs. This response is considered to be not clinically relevant. Tamsulosin showed no relevant genotoxic properties. Increased incidences of proliferative changes of mammary glands of female rats and mice have been reported. These findings, which are probably mediated by hyperprolactinemia and only occurred at high dose levels, are regarded as irrelevant.
List of excipients
Inner core tablet:
Hypromellose Microcrystalline cellulose Carbomer Colloidal anhydrous silica Iron oxide red (E172) Magnesium stearate Outer tablet: Microcrystalline cellulose Hypromellose Carbomer Colloidal anhydrous silica Magnesium stearate
Special precautions for storage
Store in the original package to protect from light.
Nature and contents of container
PVC/PVDC:Al blister packs containing 10, 18, 20, 28, 30, 50, 60, 90, 98 and 100 tablets. PVC/Aclar:Al blster packs containing 10, 18, 20, 28, 30, 50, 60, 90, 98 and 100 tablets oPA/Al/PVC/Al blster packs containing 10, 18, 20, 28, 30, 50, 60, 90, 98 and 100 Not all pack sizes may be marketed.
Special precautions for disposal
No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements.
MARKETING AUTHORISATION HOLDER
Synthon BV Microweg 22 6545 CM Nijmegen The Netherlands
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.